Paving the way to a successful AAV product

November 20th, 2024 – 4pm (CET) / 10am (ET)

Paving the way to a successful AAV product

November 20th, 2024 – 4pm (CET) / 10am (ET)

Addressed Challenges

Learning Objectives

  • Which analytical methods are appropriate for characterization of AAVs during manufacturing and drug product development?
  • Which quality attributes should be monitored during AAV manufacturing to achieve high quality products?
  • How can we measure infectivity of AAVs independent of the encoded therapeutic protein?

Prof. Dr. Susumu Uchiyama

University of Osaka, Umedico; Scientific Advisor of Coriolis Pharma

Prof. Dr. Susumu Uchiyama is a biophysical chemist with over 25 years of experience, currently a biotechnology professor at Osaka University since 2017. His research focuses on the biophysics of proteins, protein complexes, and protein-nucleic acid complexes using methods like analytical ultracentrifugation, native mass spectrometry (MS), and calorimetry. He has contributed to the development of analytical instruments and prototypes. In 2005, he worked on native MS at Prof. Carol Robinson's lab at Cambridge University. He founded U-Medico Inc. in 2006, offering analytical services since 2008. His interests include immune-related proteins, therapeutic protein formulations, and gene therapy products. He leads a national project on virus vector characterization and quality control for gene therapy. Prof. Uchiyama has published over 250 papers, edited a book, and serves on editorial boards of major journals.
Read More >>>

Melanie Schwerdtfeger Ph.D

Coriolis Pharma; Scientist ATMP formulation

Dr. Melanie Schwerdtfeger studied molecular medicine at the University of Regensburg, Germany with a focus on immunology and viral vaccine vectors. She received her PhD in biochemical and biotechnological sciences from the University of Campania “Luigi Vanvitelli”, Naples, Italy in collaboration with the Ludwig-Maximilians-Universität in Munich, Germany. During her PhD she gained expertise in the field of cancer immunotherapy working on a modular platform for adoptive T cell therapy and characterizing a novel chimeric antigen receptor. In 2021 she joined Coriolis as scientist in the ATMP group and is currently responsible for potency assay development.
Read More >>>

<span>By ticking this box, you agree to the privacy policies of <a href=”https://www.coriolis-pharma.com/data-privacy/” style=”color:white; text-decoration: underline;” target=”_blank”>Coriolis Pharma</a> and <a href=”/wp-content/uploads/2023/08/Livestorm-privacy-policy-en.pdf” style=”color:white; text-decoration: underline;” target=”_blank”>Livestorm</a>, consenting to receiving communications related to this topic and other products or services within their portfolio</span>

Dark